1
|
Chi Y, Zhu X, Chen Y, Li X, Jiang Z, Jian X, Lian M, Wu X, Wang L, Sun M, Shi X. Metabolic activation and cytochrome P450 inhibition of piperlonguminine mediated by CYP3A4. Int J Biol Macromol 2024; 268:131502. [PMID: 38626834 DOI: 10.1016/j.ijbiomac.2024.131502] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/07/2024] [Revised: 04/07/2024] [Accepted: 04/08/2024] [Indexed: 05/03/2024]
Abstract
Piperlonguminine (PLG) is a major alkaloid found in Piper longum fruits. It has been shown to possess a variety of biological activities, including anti-tumor, anti-hyperlipidemic, anti-renal fibrosis and anti-inflammatory properties. Previous studies have reported that PLG inhibits various CYP450 enzymes. The main objective of this study was to identify reactive metabolites of PLG in vitro and assess its ability to inhibit CYP450. In rat and human liver microsomal incubation systems exposed to PLG, two oxidized metabolites (M1 and M2) were detected. Additionally, in microsomes where N-acetylcysteine was used as a trapping agent, N-acetylcysteine conjugates (M3, M4, M5 and M6) of four isomeric O-quinone-derived reactive metabolites were found. The formation of metabolites was dependent on NADPH. Inhibition and recombinant CYP450 enzyme incubation experiments showed that CYP3A4 was the primary enzyme responsible for the metabolic activation of PLG. This study characterized the O-dealkylated metabolite (M1) through chemical synthesis. The IC50 shift assay showed time-dependent inhibition of CYP3A4, 2C9, 2E1, 2C8 and 2D6 by PLG. This research contributes to the understanding of PLG-induced enzyme inhibition and bioactivation.
Collapse
Affiliation(s)
- Yuqian Chi
- Hebei Key Laboratory of Innovative Drug Development and Evaluation, School of Pharmaceutical Sciences, Hebei Medical University, Shijiazhuang 050017, China; National Demonstration Center for Experimental Pharmacy Education, School of Pharmaceutical Sciences, Hebei Medical University, Shijiazhuang 050017, China
| | - Xiaoliang Zhu
- Hebei Key Laboratory of Innovative Drug Development and Evaluation, School of Pharmaceutical Sciences, Hebei Medical University, Shijiazhuang 050017, China; National Demonstration Center for Experimental Pharmacy Education, School of Pharmaceutical Sciences, Hebei Medical University, Shijiazhuang 050017, China
| | - Yaxuan Chen
- Hebei Key Laboratory of Innovative Drug Development and Evaluation, School of Pharmaceutical Sciences, Hebei Medical University, Shijiazhuang 050017, China; National Demonstration Center for Experimental Pharmacy Education, School of Pharmaceutical Sciences, Hebei Medical University, Shijiazhuang 050017, China
| | - Xin Li
- Hebei Key Laboratory of Innovative Drug Development and Evaluation, School of Pharmaceutical Sciences, Hebei Medical University, Shijiazhuang 050017, China; National Demonstration Center for Experimental Pharmacy Education, School of Pharmaceutical Sciences, Hebei Medical University, Shijiazhuang 050017, China
| | - Ziyi Jiang
- Hebei Key Laboratory of Innovative Drug Development and Evaluation, School of Pharmaceutical Sciences, Hebei Medical University, Shijiazhuang 050017, China; National Demonstration Center for Experimental Pharmacy Education, School of Pharmaceutical Sciences, Hebei Medical University, Shijiazhuang 050017, China
| | - Xiaoyang Jian
- Hebei Key Laboratory of Innovative Drug Development and Evaluation, School of Pharmaceutical Sciences, Hebei Medical University, Shijiazhuang 050017, China; National Demonstration Center for Experimental Pharmacy Education, School of Pharmaceutical Sciences, Hebei Medical University, Shijiazhuang 050017, China
| | - Mengyuan Lian
- Hebei Key Laboratory of Innovative Drug Development and Evaluation, School of Pharmaceutical Sciences, Hebei Medical University, Shijiazhuang 050017, China; National Demonstration Center for Experimental Pharmacy Education, School of Pharmaceutical Sciences, Hebei Medical University, Shijiazhuang 050017, China
| | - Xiaodi Wu
- Hebei Key Laboratory of Innovative Drug Development and Evaluation, School of Pharmaceutical Sciences, Hebei Medical University, Shijiazhuang 050017, China; National Demonstration Center for Experimental Pharmacy Education, School of Pharmaceutical Sciences, Hebei Medical University, Shijiazhuang 050017, China
| | - Lei Wang
- Hebei Key Laboratory of Innovative Drug Development and Evaluation, School of Pharmaceutical Sciences, Hebei Medical University, Shijiazhuang 050017, China; National Demonstration Center for Experimental Pharmacy Education, School of Pharmaceutical Sciences, Hebei Medical University, Shijiazhuang 050017, China; National Key Laboratory of New Pharmaceutical Preparations and excipients, School of Pharmaceutical Sciences, Hebei Medical University, Shijiazhuang 050017, China
| | - Mengmeng Sun
- General Practice Department, The Second Hospital of Hebei Medical University, Shijiazhuang 050000, China.
| | - Xiaowei Shi
- Hebei Key Laboratory of Innovative Drug Development and Evaluation, School of Pharmaceutical Sciences, Hebei Medical University, Shijiazhuang 050017, China; National Demonstration Center for Experimental Pharmacy Education, School of Pharmaceutical Sciences, Hebei Medical University, Shijiazhuang 050017, China; National Key Laboratory of New Pharmaceutical Preparations and excipients, School of Pharmaceutical Sciences, Hebei Medical University, Shijiazhuang 050017, China.
| |
Collapse
|
2
|
Li J, Shi J, Jia C, Li W, Peng Y, Zheng J. Metabolic Activation and Cytotoxicity of Propafenone Mediated by CYP2D6. Chem Res Toxicol 2022; 35:829-839. [PMID: 35442037 DOI: 10.1021/acs.chemrestox.2c00013] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
Abstract
Propafenone (PPF) is a class IC antidysrhythmic drug, which is commonly used for the treatment of atrial fibrillation and other supraventricular arrhythmias. It is also a β-adrenoceptor antagonist that can cause bradycardia and bronchospasm. Hepatotoxicity is one of the adverse reactions reported, with clinical manifestations including acute cholestasis and hepatocyte necrosis. However, the mechanism of PPF-induced hepatotoxicity remains unclear. The present study was conducted to identify reactive metabolite(s) to determine related metabolic pathways and define the possible association of the bioactivation with PPF cytotoxicity. An O-demethylation phase I metabolite (M1), a further position C5 hydroxylation (para-position of the benzene ring) metabolite (M2), glutathione (GSH) conjugates (M3 and M4), and N-acetylcysteine (NAC) conjugates (M5 and M6) were detected in rat liver microsomal incubations containing PPF and GSH or NAC as trapping agents. The corresponding GSH conjugates and NAC conjugates were found in the bile and urine of rats after PPF administration, respectively. The observed GSH and NAC conjugates indicate that a quinone metabolite was generated in vitro and in vivo. Recombinant P450 enzyme incubations showed that CYP2D6 was the principal enzyme catalyzing this metabolic activation. Quinidine, a selective inhibitor of CYP2D6, attenuated the susceptibility of hepatocytes to the cytotoxicity of PPF. The results suggest that PPF was metabolized to a p-quinone intermediate which may be involved in PPF-induced hepatotoxicity.
Collapse
Affiliation(s)
- Jiaru Li
- Wuya College of Innovation, Shenyang Pharmaceutical University, Shenyang, Liaoning 110016, P. R. China
| | - Junzu Shi
- Wuya College of Innovation, Shenyang Pharmaceutical University, Shenyang, Liaoning 110016, P. R. China
| | - Chenyang Jia
- Wuya College of Innovation, Shenyang Pharmaceutical University, Shenyang, Liaoning 110016, P. R. China
| | - Wei Li
- Wuya College of Innovation, Shenyang Pharmaceutical University, Shenyang, Liaoning 110016, P. R. China
| | - Ying Peng
- Wuya College of Innovation, Shenyang Pharmaceutical University, Shenyang, Liaoning 110016, P. R. China
| | - Jiang Zheng
- Wuya College of Innovation, Shenyang Pharmaceutical University, Shenyang, Liaoning 110016, P. R. China.,State Key Laboratory of Functions and Applications of Medicinal Plants, Key Laboratory of Pharmaceutics of Guizhou Province, Guizhou Medical University, Guiyang, Guizhou 550025, P. R. China.,Key Laboratory of Environmental Pollution, Monitoring and Disease Control, Ministry of Education, Guizhou Medical University, Guiyang, Guizhou 550025, P. R. China
| |
Collapse
|
3
|
Hou FJ, Guo LX, Zheng KY, Song JN, Wang Q, Zheng YG. Chelidonine enhances the antitumor effect of lenvatinib on hepatocellular carcinoma cells. Onco Targets Ther 2019; 12:6685-6697. [PMID: 31695406 PMCID: PMC6707434 DOI: 10.2147/ott.s215103] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/09/2019] [Accepted: 08/08/2019] [Indexed: 12/15/2022] Open
Abstract
Background Lenvatinib is a newly approved molecular targeted drug for the treatment of advanced hepatocellular carcinoma (HCC). However, the high cost associated with this treatment poses a huge financial burden on patients and the entire public health system. Therefore, there is an urgent need to develop novel strategies that enhance the antitumor effect of lenvatinib. Methods The antitumor effects of chelidonine or/and lenvatinib on HCC cell lines MHCC97-H and LM-3 were examined using the 3-[4,5-dimethyl-2-thiazolyl]-2,5-diphenyl-2- H-tetrazolium bromide (MTT) assay. For the in-vivo investigation, the effect on subcutaneous or intrahepatic tumor growth in nude mice was also determined. The mRNA levels of epithelial mesenchymal transition (EMT)-related factors were examined through quantitative polymerase chain reaction or Western blot. Results In the present study, we found that treatment with chelidonine enhanced the apoptotic effect of lenvatinib on HCC cells and the in-vivo growth of HCC tumors in nude mice. Mechanistically, treatment with chelidonine increased the expression of epithelial indicator E-cadherin, whereas it decreased the expression of mesenchymal indicators N-cadherin and Vimentin. These findings suggest that chelidonine restricted the EMT in HCC cells. Conclusion Chelidonine inhibits the process of EMT and enhances the antitumor effect of lenvatinib on HCC cells.
Collapse
Affiliation(s)
- Fang-Jie Hou
- Hebei University of Chinese Medicine, Shijiazhuang City, Hebei Province 050200, People's Republic of China
| | - Li-Xiao Guo
- Hebei University of Chinese Medicine, Shijiazhuang City, Hebei Province 050200, People's Republic of China
| | - Kai-Yan Zheng
- Hebei University of Chinese Medicine, Shijiazhuang City, Hebei Province 050200, People's Republic of China
| | - Jun-Na Song
- Hebei University of Chinese Medicine, Shijiazhuang City, Hebei Province 050200, People's Republic of China
| | - Qian Wang
- Hebei University of Chinese Medicine, Shijiazhuang City, Hebei Province 050200, People's Republic of China
| | - Yu-Guang Zheng
- Hebei University of Chinese Medicine, Shijiazhuang City, Hebei Province 050200, People's Republic of China
| |
Collapse
|